Polycystic ovary syndrome (PCOS) has affected 1 in 8 women worldwide, roughly 170 million people, yet its name has long been a problem. The previous name implied ovarian cysts, when in reality the condition entails multiple and diverse endocrine and metabolic issues. A global group of doctors and researchers published a consensus in The Lancet and officially renamed the condition polyendocrine metabolic ovarian syndrome (PMOS). As a reproductive physician, I believe this change is a significant step for patients, clinicians, and research.

Why was the name changed from PCOS to PMOS?

The old name was misleading. “Polycystic” suggested the presence of pathological ovarian cysts, but research shows these are not a true feature of the condition. Instead, PMOS is a complex multisystem condition driven by disruption in multiple hormones (polyendocrine), metabolic pathways (including insulin resistance, obesity, Type 2 diabetes risk, and cardiovascular issues), and ovarian function.

PMOS also contributes to irregular periods, infertility, acne, excess hair growth, anxiety, depression, and long-term health effects. The narrow reproductive focus of “PCOS” obscured these broader impacts, leading to delayed diagnosis in up to 70% of cases, fragmented care, patient frustration, and unnecessary sigma.

What does this name change mean for patients?

As a reproductive endocrinologist and obstetrician gynecologist, I am still a primary care provider even though I focus on helping patients become pregnant. This new name with a multisystem focus will help all health care providers better take care of our patients with PMOS. We can help patients obtain healthier lives by educating them and hopefully preventing insulin resistance, obesity, Type 2 diabetes, and cardiovascular disease.

For years, patients and advocacy groups called for a name change. In 2025 and 2026, a global process including 14,360 people with PMOS and multidisciplinary health professionals from every world region participated in surveys and workshops. Principles prioritized scientific accuracy, clarity, stigma reduction, cultural appropriateness, and practical implementation. The result? Polyendocrine metabolic ovarian syndrome (PMOS), a name that accurately reflects the endocrine, metabolic, and ovarian roots of the disorder while dropping the inaccurate “cysts” reference.

Why does this matter?

First, it improves communication. Patients and doctors can now discuss the full picture rather than a misleading label. Second, it reduces stigma and empowers earlier diagnosis and holistic care. Third, it aligns research, guidelines, and policy with the condition’s true nature, potentially accelerating better treatments and funding. Global implementation is underway: three-year transition, updated patient resources, integration into electronic health records and medical coding, and the next international guideline update in 2028.

If you or someone you know has been diagnosed with PCOS (now PMOS), know that this name change is more than semantics, it’s a recognition of the full scope of the condition and a commitment to better health comes. I encourage anyone with symptoms of irregular cycles, excess hair or acne, weight challenges, or fertility concerns, to speak with their doctor. Early recognition and comprehensive management make a real difference.